Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by Wall Street Zen

Dyne Therapeutics (NASDAQ:DYN) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday.

DYN has been the subject of several other research reports. Robert W. Baird set a $30.00 price objective on Dyne Therapeutics in a research note on Monday, December 8th. Raymond James Financial reiterated a “strong-buy” rating and issued a $40.00 price target on shares of Dyne Therapeutics in a research note on Monday, December 8th. Cowen reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus increased their target price on Dyne Therapeutics from $36.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.47.

Dyne Therapeutics Trading Down 1.5%

Shares of Dyne Therapeutics stock opened at $20.04 on Friday. The company has a market cap of $2.86 billion, a P/E ratio of -5.48 and a beta of 1.30. Dyne Therapeutics has a fifty-two week low of $6.36 and a fifty-two week high of $26.22. The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.47 and a current ratio of 13.47. The firm has a 50-day simple moving average of $20.17 and a two-hundred day simple moving average of $14.74.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.05. As a group, equities analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Darwin Wealth Management LLC lifted its stake in Dyne Therapeutics by 0.5% in the third quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock valued at $2,195,000 after buying an additional 861 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after acquiring an additional 955 shares during the period. Creative Planning raised its position in Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after purchasing an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Dyne Therapeutics by 25.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after purchasing an additional 1,109 shares during the period. Finally, Caxton Associates LLP boosted its stake in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after purchasing an additional 1,627 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.